Literature DB >> 12172100

Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals.

Lynn E Taylor, Theresa Costello, Elizabeth Alt, Gail Yates, Karen Tashima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12172100     DOI： 10.1097/00002030-200208160-00024

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  10 in total

1.  Barriers to accessing care in patients with chronic hepatitis C: the impact of depression.

Authors:  D M Evon; K M Simpson; D Esserman; A Verma; S Smith; M W Fried
Journal:  Aliment Pharmacol Ther       Date:  2010-09-17       Impact factor: 8.171

2.  Psychiatric care of the patient with hepatitis C: a review of the literature.

Authors:  Muhamad Aly Rifai; Ondria C Gleason; Douha Sabouni
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.

Authors:  Lynn E Taylor; Sarah E Bowman; Stacey Chapman; Nickolas Zaller; Michael D Stein; Patricia A Cioe; Michaela A Maynard; Barbara Hedgis McGovern
Journal:  Drug Alcohol Depend       Date:  2010-12-21       Impact factor: 4.492

4.  Patient and provider characteristics associated with the decision of HIV coinfected patients to start hepatitis C treatment.

Authors:  Karen Chan Osilla; Glenn Wagner; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Mallory Witt; Laveeza Bhatti; Matthew Bidwell Goetz
Journal:  AIDS Patient Care STDS       Date:  2011-08-08       Impact factor: 5.078

5.  Treat early or wait and monitor? A qualitative analysis of provider hepatitis C virus treatment decision-making in the context of HIV coinfection.

Authors:  Glenn Wagner; Gery Ryan; Karen Chan Osilla; Laveeza Bhatti; Matthew Goetz; Mallory Witt
Journal:  AIDS Patient Care STDS       Date:  2009-09       Impact factor: 5.078

6.  Factors that influence an HIV coinfected patient's decision to start hepatitis C treatment.

Authors:  Karen Chan Osilla; Gery Ryan; Laveeza Bhatti; Matthew Goetz; Mallory Witt; Glenn Wagner
Journal:  AIDS Patient Care STDS       Date:  2009-12       Impact factor: 5.078

Review 7.  HBV plus HCV, HCV plus HIV, HBV plus HIV.

Authors:  James S Park; Neeraj Saraf; Douglas T Dieterich
Journal:  Curr Gastroenterol Rep       Date:  2006-02

8.  Provider and patient correlates of provider decisions to recommend HCV treatment to HIV co-infected patients.

Authors:  Glenn Wagner; Karen Chan Osilla; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Laveeza Bhatti; Mallory Witt; Matthew Bidwell Goetz
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2012-05-07

9.  Pegylated interferon alpha-2a with or without ribavirin in HCV/HIV coinfection: partially blinded, randomized multicenter trial.

Authors:  Mandana Khalili; David Bernstein; Ellen Lentz; Christine Barylski; Margaret Hoffman-Terry
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.487

10.  Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients.

Authors:  Glenn Wagner; Karen Chan Osilla; Jeffrey Garnett; Bonnie Ghosh-Dastidar; Laveeza Bhatti; Matthew Bidwell Goetz; Mallory Witt
Journal:  AIDS Res Treat       Date:  2011-10-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.